The short answer
- Controlled hypothyroidism is usually standard, often with no rating at all.
- Treated Graves disease prices slightly less generously but is routinely approved.
- An uninvestigated nodule is the one thing that reliably causes a postpone.
- Thyroid cancer is underwritten as cancer, not as thyroid disease.
Where you stand
Most thyroid disease is a non-event
Hypothyroidism on a stable dose, with normal TSH results, is one of the mildest conditions in underwriting. Many applicants are approved at the same rate they would have received with no thyroid history at all.
Check my options →What decides your rate
Thyroid underwriting is unusually straightforward, and turns on a short list:
- Which condition - underactive, overactive, or a nodule
- Whether your levels are controlled on current treatment
- Medication stability - a settled dose beats one being adjusted
- Any cardiac complication, since long-standing untreated overactivity can affect the heart
- Whether a nodule has been investigated, and what the biopsy showed
What each situation typically means
| Your situation | Realistic route |
|---|---|
| Hypothyroidism, controlled on a stable dose | Standard, often no rating |
| Hashimoto thyroiditis, controlled | Standard |
| Graves disease treated, levels normal | Standard to mild rating |
| Hyperthyroidism, recently diagnosed or being treated | Mild rating or short postpone |
| Thyroid nodule, biopsy benign | Standard |
| Thyroid nodule, not yet investigated | Postpone until resolved |
Get the nodule investigated first
If you have a thyroid nodule that has not been imaged or biopsied, resolve it before you apply. An uninvestigated nodule is the most common reason a straightforward thyroid application gets postponed, because the underwriter cannot rule out what it might be. Once it comes back benign, the application usually proceeds normally.
Why thyroid disease is treated so lightly
Thyroid conditions are common, well understood, cheaply monitored and highly treatable. Once levels are controlled, the excess mortality attached to hypothyroidism is close to negligible - which is exactly what an underwriter is measuring.
That makes this one of the few conditions where hunting for a specialist carrier is unnecessary. Most mainstream carriers treat a controlled thyroid history as unremarkable, so ordinary competitive pricing applies to you.
Where thyroid disease stops being simple
Two situations change the picture. The first is thyroid cancer, which is assessed under cancer rules by type, stage and time since treatment - see life insurance after a cancer diagnosis. Papillary thyroid cancer generally carries a strong prognosis and is often underwritten more favourably than most cancers.
The second is long-standing overactivity that has affected the heart, particularly where it has caused atrial fibrillation. At that point the cardiac history drives the rating rather than the thyroid - see life insurance with heart disease.
The order to apply
- Get a recent TSH result - a current normal reading does most of the work
- Resolve any nodule before applying, not during
- Confirm your dose has been stable, and for how long
- Apply normally - controlled thyroid disease rarely needs a specialist carrier
Common questions
Does hypothyroidism affect life insurance rates?+
Usually not. Hypothyroidism controlled on a stable dose, with normal TSH results, is commonly approved at standard rates with no rating at all. It is one of the mildest conditions in underwriting.
Will taking levothyroxine flag my application?+
It will appear in prescription records, and that is fine. Treated, stable thyroid disease is what underwriters want to see. A dose still being adjusted attracts more attention than a settled one.
What if I have a thyroid nodule?+
Get it investigated first. A nodule with a benign biopsy is generally treated as standard. A nodule that has not yet been imaged or biopsied is usually postponed, because the underwriter cannot price an unknown.
Is thyroid cancer underwritten differently?+
Yes. Thyroid cancer is assessed under cancer rules, by type, stage and time since treatment, rather than as thyroid disease. Papillary thyroid cancer has a strong prognosis and is often underwritten more favourably than most cancers.